Literature DB >> 30559432

Multiplexed orthogonal genome editing and transcriptional activation by Cas12a.

Marco Breinig1, Anabel Y Schweitzer1, Anna M Herianto1, Steffie Revia1, Lisa Schaefer1, Lena Wendler1, Ana Cobos Galvez1, Darjus F Tschaharganeh2.   

Abstract

CRISPR-Cas9-based combinatorial perturbation approaches for orthogonal knockout and gene activation have been impeded by complex vector designs and co-delivery of multiple constructs. Here, we demonstrate that catalytically active CRISPR-Cas12a fused to a transcriptional-activator domain enables flexible switching between genome editing and transcriptional activation by altering guide length. By leveraging Cas12a-mediated CRISPR-RNA array processing, we illustrate that Cas12a-VPR enables simplified multiplexed knockout and transcriptional activation in vitro and in vivo.

Entities:  

Mesh:

Year:  2018        PMID: 30559432     DOI: 10.1038/s41592-018-0262-1

Source DB:  PubMed          Journal:  Nat Methods        ISSN: 1548-7091            Impact factor:   28.547


  20 in total

Review 1.  Integration of CRISPR-engineering and hiPSC-based models of psychiatric genomics.

Authors:  Marliette R Matos; Seok-Man Ho; Nadine Schrode; Kristen J Brennand
Journal:  Mol Cell Neurosci       Date:  2020-07-23       Impact factor: 4.314

Review 2.  Exploring the Trans-Cleavage Activity of CRISPR-Cas12a (cpf1) for the Development of a Universal Electrochemical Biosensor.

Authors:  Yifan Dai; Rodrigo A Somoza; Liu Wang; Jean F Welter; Yan Li; Arnold I Caplan; Chung Chiun Liu
Journal:  Angew Chem Int Ed Engl       Date:  2019-10-17       Impact factor: 15.336

Review 3.  Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.

Authors:  Sudhanshu P Raikwar; Nidhi S Kikkeri; Ragha Sakuru; Daniyal Saeed; Haris Zahoor; Keerthivaas Premkumar; Shireen Mentor; Ramasamy Thangavel; Iuliia Dubova; Mohammad Ejaz Ahmed; Govindhasamy P Selvakumar; Duraisamy Kempuraj; Smita Zaheer; Shankar S Iyer; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-23       Impact factor: 4.147

4.  Boosting plant genome editing with a versatile CRISPR-Combo system.

Authors:  Changtian Pan; Gen Li; Aimee A Malzahn; Yanhao Cheng; Benjamin Leyson; Simon Sretenovic; Filiz Gurel; Gary D Coleman; Yiping Qi
Journal:  Nat Plants       Date:  2022-05-20       Impact factor: 17.352

Review 5.  Green Revolution to Gene Revolution: Technological Advances in Agriculture to Feed the World.

Authors:  Mohd Fadhli Hamdan; Siti Nurfadhlina Mohd Noor; Nazrin Abd-Aziz; Teen-Lee Pua; Boon Chin Tan
Journal:  Plants (Basel)       Date:  2022-05-12

6.  crRNA complementarity shifts endogenous CRISPR-Cas systems between transcriptional repression and DNA defense.

Authors:  Hannah K Ratner; David S Weiss
Journal:  RNA Biol       Date:  2021-03-18       Impact factor: 4.652

7.  The bridge helix of Cas12a imparts selectivity in cis-DNA cleavage and regulates trans-DNA cleavage.

Authors:  Hari Priya Parameshwaran; Kesavan Babu; Christine Tran; Kevin Guan; Aleique Allen; Venkatesan Kathiresan; Peter Z Qin; Rakhi Rajan
Journal:  FEBS Lett       Date:  2021-02-28       Impact factor: 4.124

8.  Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity.

Authors:  Hongxin Huang; Guanjie Huang; Zhihong Tan; Yongfei Hu; Lin Shan; Jiajian Zhou; Xin Zhang; Shufeng Ma; Weiqi Lv; Tao Huang; Yuchen Liu; Dong Wang; Xiaoyang Zhao; Ying Lin; Zhili Rong
Journal:  BMC Biol       Date:  2022-04-25       Impact factor: 7.364

9.  Synthetic immunomodulation with a CRISPR super-repressor in vivo.

Authors:  Ryan LeGraw; Jeremy J Velazquez; Farzaneh Moghadam; Nan Cher Yeo; Chenxi Xu; Jin Park; Alejandro Chavez; Mo R Ebrahimkhani; Samira Kiani
Journal:  Nat Cell Biol       Date:  2020-09-03       Impact factor: 28.824

Review 10.  CRISPR-Based Synthetic Transcription Factors In Vivo: The Future of Therapeutic Cellular Programming.

Authors:  Matthew Pandelakis; Elizabeth Delgado; Mo R Ebrahimkhani
Journal:  Cell Syst       Date:  2020-01-22       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.